Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
09/2005
09/22/2005WO2004071451A3 Random alkylene oxide copolymers for medical and surgical utilities
09/22/2005WO2004060265A3 Eye-drop vaccine containing copolymer 1 for therapeutic immunization
09/22/2005US20050209606 Alginate viscoelastic composition, method of use and package
09/22/2005US20050209416 Linking a sulfur compound directly to a terminal carbon of polyethyleneglycol, polyalkylene oxides or a polyvinyl alcohol; converting the sulfur to an active ethyl sulfone group having a reactive site located at the second carbon from the sulfone group; modifying biologically active molecules
09/22/2005US20050209345 Lymphatic drug delivery system
09/22/2005US20050209343 Percutaneous absorption promoters and compositions for treating athlete's foot
09/22/2005US20050209265 Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
09/22/2005US20050209229 Form 3 ZD1839 dimethylsulfoxide solvate; ZD1839 is known as the tradename Iressa and as gefitinib
09/22/2005US20050209207 Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery
09/22/2005US20050209206 Pharmaceutical formulation comprising an androstane derivative and a solubilising agent in an aqueous liquid carrier
09/22/2005US20050209192 Autoimmune disorders; modulating protein kinase C activity
09/22/2005US20050209190 Camptothecin complexes
09/22/2005US20050209174 Especially conjugating derivatives of paclitaxel, cholesterol, camptothecin, and rhodamine123 to transferrins, side effect reduction
09/22/2005US20050209173 Neurodegenerative protein aggregation inhibition methods and compounds
09/22/2005US20050209159 Effectors of dipeptidyl peptidase IV for topical use
09/22/2005US20050209147 Containing a transport domain, a linker and a RhoA domain; antiinflammatory agents in the inhibition of leukocyte adhesion and migration, antiarthritic, antiproliferative, antimetastasis, and antifibrotic agents
09/22/2005US20050209146 Administering bifunctional molecules containing a drug moiety and presenter protein ligand for therapy
09/22/2005US20050209144 Protein formulations
09/22/2005US20050208528 Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
09/22/2005US20050208498 Killer cell immunoglobulin-like receptor (KIR)-like protein receptor for use in diagnosis, prevention and treatment of cancer, autoimmune disease, organ transplant rejection, allergic reaction, and inflammatory disorders
09/22/2005US20050208200 Multilayer, biocompatible overcoatings containing heparin; stents
09/22/2005US20050208190 Method for drying neotame with co-agents
09/22/2005US20050208154 Antidepressants for treating manic disorders, psychosis; comprising ethyl cellulose, talc, polyvinylpyrrolidone; time-release dosage form; once daily
09/22/2005US20050208145 beta-glucan concentrate has a honeycomb structure; subjecting the fiber residue from oat or barley flour/alcohol slurry to sonication, protease or amylase treatment or combination treatment; use as encapsulating agent; absorption or release of drug in lower intestinal tract; sustained release
09/22/2005US20050208142 Production of nanoparticles having a defined number of ligands
09/22/2005US20050208139 comprising Z isomeric form and E isomeric form of 4-hydroxy tamoxifen; not affected the drug potency; drug mixture in a gel, a solution, patch, in a unit dose packet or in a multiple dose container with a metered pump; new drug form; drug delivery device
09/22/2005US20050208138 Injection of a biocompatible polymer, polysaccharide or polyamino acid, a cross-linker, and therapeutic agent into tumor; hydrogel formed in the tumor retains the therapeutic agent; drug delivery method; sustained releasing the biodrug
09/22/2005US20050208137 comprising angiogenesis inhibitor retinoic acid, taxol and polymeric carrier polylactone; treating cancer, angiogenic-dependent diseases, embolizing blood vessels, and eliminating biliary, urethral, esophageal, tracheal/bronchial obstructions, corneal neovascularization; coated stents with the mixture
09/22/2005US20050208136 Antitumor agent and process for producing the same
09/22/2005US20050208135 Monocompartment osmotic controlled drug delivery system
09/22/2005US20050208129 Prolonged release bioadhesive therapeutic systems
09/22/2005US20050208128 Immediate release tablet
09/22/2005US20050208126 Chemical ifg-i composition for the treatment and prevention of neurodgenerative diseases
09/22/2005US20050208122 Biodegradable biocompatible implant and method of manufacturing same
09/22/2005US20050208119 Preparations of chelating agents encapsulated in micelles or liposomes; comprising alpha lipoic acid and micelles or liposomes containing EDTA or other chelators and magnesium chloride; for transferring antioxidant and chelating agent, across cell membrane; therapy for toxic heavy metal poisoning
09/22/2005US20050208106 Composition containing oat straw and willow herb extract
09/22/2005US20050208102 Sustained release delivery systems; contact lens shape; includes vision correction; lower dosage antiangiogenesis therapeutics; reduced local inflammation and/or adverse systemic reactions; macular degeneration; retinopathies
09/22/2005US20050208092 Drug delivery; vascular disease; stents, grafts, anastomotic devices, perivascular wraps, sutures and staples
09/22/2005US20050208081 With water miscible solubilizer; phosphodiesterase inhibitors; cardiovascular disorders
09/22/2005US20050208076 Combined with recombinant human serum albumin
09/22/2005US20050208056 Neoplasm specific antibodies and uses thereof
09/22/2005US20050208043 Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
09/22/2005US20050208035 Nutritional composition for treating an immune condition
09/22/2005US20050208015 Glycerol derivative
09/22/2005US20050207990 Stabilised supersaturated solids of lipophilic drugs
09/22/2005US20050207989 High storage stability inhalable compositions
09/22/2005US20050207988 Polysaccharides for pulmonary delivery of active agents
09/22/2005US20050207984 Physical and chemical stability; homogeneity; particle size range; asthma, chronic obstructive pulmonary disease; 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane used as propellants
09/22/2005US20050207983 treatment of respiratory system disorders comprising administering non-surfactant aerosols comprising sodium chloride as a diluent and drugs selected from antibiotics, antihistamines and/or antiviral agents
09/22/2005US20050207980 Stable microbubbles suspensions injectable into living organisms
09/22/2005US20050207974 antibodies, fragments or ligands that specifically binds to polypeptides or polynucleotides that are differentially expressed in vascular endothelial cells, conjugated to drugs or cytotoxic agents such as angiogenesis inhibitors or activators; treatment of vascular diseases; inhibiting tumor growth
09/22/2005US20050206023 formation of particles of a target substance, such as a pharmaceutical, using a supercritical or near-critical fluid as an anti-solvent
09/22/2005US20050205083 Medicament storage and delivery devices
09/22/2005DE20321052U1 Transdermal therapeutic system for delivery of fentanyl, to treat severe and/or chronic pain, including drug-containing adhesive matrix of specific basic acrylate copolymer requiring no penetration accelerators
09/22/2005DE102004009904A1 Kit aus einem gegebenenfalls wirkstoffhaltigen Pflaster und einem Hautirritationen verhindernden Mittel Kit preventing from an optionally medicated plaster and a skin irritation means
09/22/2005DE102004009903A1 Pflaster mit reduzierter Hautirritation Paving with reduced skin irritation
09/22/2005DE10152351B4 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat Solid pharmaceutical formulation for a Piperazinharnstoffderivat
09/22/2005CA2560079A1 Process for producing medicine
09/22/2005CA2560076A1 Method of preparing a protein aggregate and a pharmaceutical composition
09/22/2005CA2559800A1 Drug delivery system based on immune response system
09/22/2005CA2559351A1 Novel compositions for topical delivery
09/22/2005CA2558582A1 Stabilised supersaturated solids of lipophilic drugs
09/22/2005CA2558266A1 Reagents, methods and kits for use in deactivating nucleic acids
09/22/2005CA2558219A1 Poorly water-soluble drug-containing solid formulation
09/22/2005CA2555250A1 Anti-infectious hydrogel compositions
09/22/2005CA2533878A1 Fluorinated carbohydrate conjugates
09/22/2005CA2499220A1 Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
09/21/2005EP1577828A2 A method of anti-counterfeit marking a product which is manufactured with a stable non-radioactive isotope
09/21/2005EP1577361A1 Spraying composition
09/21/2005EP1576961A1 Pharmaceutical compound containing silymarin and carbopol, production method thereof and use of same as a regenerator of tissue and pancreatic cells with endogenous secretion damaged by diabetes mellitus
09/21/2005EP1576953A1 Propofol-containing fat emulsions
09/21/2005EP1576891A1 Method for drying neotame with co-agents
09/21/2005EP1576170A2 Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer
09/21/2005EP1576150A2 Methods and compositions for increasing the efficacy of biologically-active ingredients
09/21/2005EP1576132A2 Nucleic acids and corresponding proteins entitled 273p4b7 useful in treatment and detection of cancer
09/21/2005EP1576130A2 Nucleic acids and corresponding proteins entitled 282p1g3 useful in treatment and detection of cancer
09/21/2005EP1576105A2 Stabilized anti-respiratory syncytial virus (rsv) antibody formulations
09/21/2005EP1576104A2 Nucleic acids and corresponding proteins entitled 202p5a5 useful in treatment and detection of cancer
09/21/2005EP1576100A2 Purified composition of bispecific molecules and methods of production
09/21/2005EP1576089A2 Expansion of renewable stem cell populations
09/21/2005EP1576022A1 Method for the production of an active molecule vector used to diffuse active substances and vector thus obtained
09/21/2005EP1576007A2 Methods and agents for diagnosis and prevention, amelioration or treatment of goblet cell-related disorders
09/21/2005EP1575995A2 Activation of peptide prodrugs by hk2
09/21/2005EP1575987A2 Conjugates of membrane translocating agents and pharmaceutically active agents
09/21/2005EP1575976A2 Methods and compositions for therapeutic use of rna interference
09/21/2005EP1575972A1 Nucleic acid labeling compounds
09/21/2005EP1575639A2 Drug delivery system for sustained delivery of glipizide
09/21/2005EP1575618A2 Dispersible pharmaceutical compositions
09/21/2005EP1575617A1 Use of topical pharmaceutical compositions comprising an active agent and permeation-enhancing base for the manufacture of a medicament to treat various forms of inflammatory dermatosis
09/21/2005EP1575616A2 Novel injectable depot formulations
09/21/2005EP1575600A1 Active ingredient combinations of polyhexamethylenebiguanidine hydrochloride and distearyldimethylammonium chloride and preparations comprising said active ingredient combinations
09/21/2005EP1575597A1 Use of rimexolone in the treatment of dry eye
09/21/2005EP1575588A1 Tiotropium containing hfc solution formulations
09/21/2005EP1575585A1 Pharmaceutical liquid composition containing pyridone derivative
09/21/2005EP1575577A2 Composition for the prevention and treatment of inflammation of the ear
09/21/2005EP1575571A2 Compositions and methods for the diagnosis and treatment of tumor
09/21/2005EP1575570A2 Transdermal vaccine delivery device having coated microprotrusions
09/21/2005EP1575562A2 Buoyant polymer particles delivering therapeutic agents
09/21/2005EP1575559A1 Dosing aerosols containing lecithin as a surface-active substance
09/21/2005EP1575558A2 Ophthalmic and ophthalmological use of a complex nutritive base in an aqueous medium
1 ... 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 ... 1712